Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 21;59(39):16982-16988.
doi: 10.1002/anie.202007474. Epub 2020 Aug 13.

Rabies Virus-Inspired Metal-Organic Frameworks (MOFs) for Targeted Imaging and Chemotherapy of Glioma

Affiliations

Rabies Virus-Inspired Metal-Organic Frameworks (MOFs) for Targeted Imaging and Chemotherapy of Glioma

Chaoqiang Qiao et al. Angew Chem Int Ed Engl. .

Abstract

The blood-brain barrier (BBB) restricts access to the brain of more than 98 % of therapeutic agents and is largely responsible for treatment failure of glioblastoma multiforme (GBM). Therefore, it is of great importance to develop a safe and efficient strategy for more effective drug delivery across the BBB into the brain. Inspired by the extraordinary capability of rabies virus (RABV) to enter the central nervous system, we report the development and evaluation of the metal-organic framework-based nanocarrier MILB@LR, which closely mimicked both the bullet-shape structure and surface functions of natural RABV. MILB@LR benefited from a more comprehensive RABV-mimic strategy than mimicking individual features of RABV and exhibited significantly enhanced BBB penetration and brain tumor targeting. MILB@LR also displayed superior inhibition of tumor growth when loaded with oxaliplatin. The results demonstrated that MILB@LR may be valuable for GBM targeting and treatment.

Keywords: blood-brain barrier; cancer therapy; glioma; metal-organic frameworks (MOFs); rabis virus.

PubMed Disclaimer

References

    1. None
    1. D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-Xuan, J.-Y. Delattre, Lancet 2012, 379, 1984-1996;
    1. A. Shergalis, A. Bankhead, U. Luesakul, N. Muangsin, N. Neamati, Pharmacol. Rev. 2018, 70, 412-445;
    1. E. Zanders, F. Svensson, D. Bailey, Drug Discovery Today 2019, 24, 1193-1201.
    1. None

Publication types

Substances

LinkOut - more resources